StockData
Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc. (CAPR) stock

CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$8.41+0.11 (+1.33%)

Close on Nov 17, 2026Market cap $488.95MP/E –Yield –

Capricor Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Capricor Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$135.16M. For fiscal 2025 it was -$108.14M. The highest annual figure on record is -$2.10M in fiscal 2012.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$108.14M–
FY2024Dec 31, 2024-$42.56M–
FY2023Dec 31, 2023-$24.08M–
FY2022Dec 31, 2022-$29.70M–
FY2021Dec 31, 2021-$20.94M–
FY2020Dec 31, 2020-$13.69M–
FY2019Dec 31, 2019-$7.73M–
FY2018Dec 31, 2018-$15.33M–
FY2017Dec 31, 2017-$12.86M–
FY2016Dec 31, 2016-$16.98M–
FY2015Dec 31, 2015-$12.61M–
FY2014Dec 31, 2014-$6.02M–
FY2013Dec 31, 2013-$6.90M–
FY2012Dec 31, 2012-$2.10M–
FY2011Dec 31, 2011-$4.90M–
FY2010Dec 31, 2010-$6.29M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$42.95M–
Q1 FY2026Mar 31, 2026-$36.77M–
Q4 FY2025Dec 31, 2025-$29.16M–
Q3 FY2025Sep 30, 2025-$26.28M–
Q2 FY2025Jun 30, 2025-$27.72M–
Q1 FY2025Mar 31, 2025-$24.98M–
Q4 FY2024Dec 31, 2024-$7.70M–
Q3 FY2024Sep 30, 2024-$13.01M–
Q2 FY2024Jun 30, 2024-$11.59M–
Q1 FY2024Mar 31, 2024-$10.27M–
Q4 FY2023Dec 31, 2023-$1.28M–
Q3 FY2023Sep 30, 2023-$6.86M–
Q2 FY2023Jun 30, 2023-$7.75M–
Q1 FY2023Mar 31, 2023-$8.18M–
Q4 FY2022Dec 31, 2022-$8.07M–
Q3 FY2022Sep 30, 2022-$6.48M–
Q2 FY2022Jun 30, 2022-$7.32M–
Q1 FY2022Mar 31, 2022-$7.83M–
Q4 FY2021Dec 31, 2021-$6.38M–
Q3 FY2021Sep 30, 2021-$4.31M–
Q2 FY2021Jun 30, 2021-$5.08M–
Q1 FY2021Mar 31, 2021-$5.16M–
Q4 FY2020Dec 31, 2020-$4.18M–
Q3 FY2020Sep 30, 2020-$3.91M–
Q2 FY2020Jun 30, 2020-$3.49M–
Q1 FY2020Mar 31, 2020-$2.11M–
Q4 FY2019Dec 31, 2019-$1.48M–
Q3 FY2019Sep 30, 2019-$1.63M–
Q2 FY2019Jun 30, 2019-$2.07M–
Q1 FY2019Mar 31, 2019-$2.56M–
Q4 FY2018Dec 31, 2018-$3.31M–
Q3 FY2018Sep 30, 2018-$4.17M–
Q2 FY2018Jun 30, 2018-$4.16M–
Q1 FY2018Mar 31, 2018-$3.69M–
Q4 FY2017Dec 31, 2017-$3.28M–
Q3 FY2017Sep 30, 2017-$2.64M–
Q2 FY2017Jun 30, 2017-$3.38M–
Q1 FY2017Mar 31, 2017-$3.57M–
Q4 FY2016Dec 31, 2016-$2.91M–
Q3 FY2016Sep 30, 2016-$5.24M–

More Capricor Therapeutics figures

See a number that looks wrong?